RenovoRx Initiates Phase III Trial for TAMP Therapy in Pancreatic Cancer

RenovoRx Initiates Phase III Trial for TAMP Therapy in Pancreatic Cancer

By
Felipe Rodriguez
1 min read

RenovoRx Launches Phase III Trial for Pancreatic Cancer Treatment

RenovoRx is making significant strides in the treatment of locally advanced pancreatic cancer with the enrollment of its first patient in the Phase III TIGeR-PaC trial at the University of Nebraska Medical Center (UNMC). This innovative drug-device combination therapy, designed to enhance the penetration of chemotherapy drugs into tumors, holds promise for revolutionizing pancreatic cancer treatment.

Key Takeaways

  • RenovoRx's Phase III trial aims to improve drug penetration into pancreatic tumors using the Trans-Arterial Micro-Perfusion (TAMP) therapy platform.
  • The trial will compare the effectiveness of Eli Lilly’s Gemzar (gemcitabine) administered intra-arterially alone versus a combination with Abraxane (nab paclitaxel).
  • The primary goal is to improve overall survival, with secondary objectives including reduced side effects compared to standard treatments.

Analysis

RenovoRx's groundbreaking approach addresses a significant challenge in pancreatic cancer treatment by targeting insufficient drug concentration reaching the tumor. This presents opportunities for major pharmaceutical companies and healthcare providers, with the potential to redefine treatment protocols globally and influence patient outcomes.

Did You Know?

  • Trans-Arterial Micro-Perfusion (TAMP) Therapy:
    • Explanation: TAMP therapy uses a dual-balloon infusion delivery system to administer chemotherapy directly to the tumor site, bypassing the thick layer of scar tissue that often impedes drug efficacy.
  • Dual-Balloon Infusion Delivery System:
    • Explanation: This specialized medical device is designed to deliver chemotherapy directly to pancreatic tumors, ensuring the drugs penetrate the tumor more effectively, while minimizing exposure to healthy tissues.
  • Gemzar (gemcitabine) and Abraxane (nab paclitaxel):
    • Explanation: Both chemotherapy drugs are being tested in the trial to determine their effectiveness in improving overall survival and reducing side effects compared to standard chemotherapy regimens.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings